PoplarV1, Main, Exploration, bibRecord, 003B59

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

Identifieur interne : 003B59 ( Main/Exploration ); précédent : 003B58; suivant : 003B60

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

Auteurs : Debbie Drane [Australie] ; Charmaine Gittleson ; Jeff Boyle ; Eugene Maraskovsky

Source :

Expert review of vaccines [ 1744-8395 ] ; 2007.

RBID : pubmed:17931156

Descripteurs français

KwdFr :
- Adjuvants immunologiques (administration et posologie), Adjuvants pharmaceutiques (administration et posologie), Animaux (MeSH), Association médicamenteuse (MeSH), Cholestérol (administration et posologie), Cholestérol (immunologie), Essais cliniques comme sujet (méthodes), Humains (MeSH), Phospholipides (administration et posologie), Phospholipides (immunologie), Saponines (administration et posologie), Saponines (immunologie), Vaccins (administration et posologie), Vaccins (immunologie).
MESH :
- administration et posologie : Adjuvants immunologiques, Adjuvants pharmaceutiques, Cholestérol, Phospholipides, Saponines, Vaccins.
- immunologie : Cholestérol, Phospholipides, Saponines, Vaccins.
- méthodes : Essais cliniques comme sujet.
- Animaux, Association médicamenteuse, Humains.

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Pharmaceutic (administration & dosage), Animals (MeSH), Cholesterol (administration & dosage), Cholesterol (immunology), Clinical Trials as Topic (methods), Drug Combinations (MeSH), Humans (MeSH), Phospholipids (administration & dosage), Phospholipids (immunology), Saponins (administration & dosage), Saponins (immunology), Vaccines (administration & dosage), Vaccines (immunology).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Cholesterol, Phospholipids, Saponins, Vaccines.
- chemical , immunology : Cholesterol, Phospholipids, Saponins, Vaccines.
- methods : Clinical Trials as Topic.
- Animals, Drug Combinations, Humans.

Abstract

The ISCOMATRIX adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.

DOI: 10.1586/14760584.6.5.761
PubMed: 17931156

Affiliations:

Australie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 003A51
to stream Main, to step Curation: 003A51

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.</title>
<author><name sortKey="Drane, Debbie" sort="Drane, Debbie" uniqKey="Drane D" first="Debbie" last="Drane">Debbie Drane</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria, Australia. debbie.drane@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria</wicri:regionArea>
<wicri:noRegion>3052 Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gittleson, Charmaine" sort="Gittleson, Charmaine" uniqKey="Gittleson C" first="Charmaine" last="Gittleson">Charmaine Gittleson</name>
</author>
<author><name sortKey="Boyle, Jeff" sort="Boyle, Jeff" uniqKey="Boyle J" first="Jeff" last="Boyle">Jeff Boyle</name>
</author>
<author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17931156</idno>
<idno type="pmid">17931156</idno>
<idno type="doi">10.1586/14760584.6.5.761</idno>
<idno type="wicri:Area/Main/Corpus">003A51</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003A51</idno>
<idno type="wicri:Area/Main/Curation">003A51</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003A51</idno>
<idno type="wicri:Area/Main/Exploration">003A51</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.</title>
<author><name sortKey="Drane, Debbie" sort="Drane, Debbie" uniqKey="Drane D" first="Debbie" last="Drane">Debbie Drane</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria, Australia. debbie.drane@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria</wicri:regionArea>
<wicri:noRegion>3052 Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gittleson, Charmaine" sort="Gittleson, Charmaine" uniqKey="Gittleson C" first="Charmaine" last="Gittleson">Charmaine Gittleson</name>
</author>
<author><name sortKey="Boyle, Jeff" sort="Boyle, Jeff" uniqKey="Boyle J" first="Jeff" last="Boyle">Jeff Boyle</name>
</author>
<author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name>
</author>
</analytic>
<series><title level="j">Expert review of vaccines</title>
<idno type="eISSN">1744-8395</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adjuvants, Pharmaceutic (administration & dosage)</term>
<term>Animals (MeSH)</term>
<term>Cholesterol (administration & dosage)</term>
<term>Cholesterol (immunology)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Drug Combinations (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Phospholipids (administration & dosage)</term>
<term>Phospholipids (immunology)</term>
<term>Saponins (administration & dosage)</term>
<term>Saponins (immunology)</term>
<term>Vaccines (administration & dosage)</term>
<term>Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adjuvants pharmaceutiques (administration et posologie)</term>
<term>Animaux (MeSH)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Cholestérol (administration et posologie)</term>
<term>Cholestérol (immunologie)</term>
<term>Essais cliniques comme sujet (méthodes)</term>
<term>Humains (MeSH)</term>
<term>Phospholipides (administration et posologie)</term>
<term>Phospholipides (immunologie)</term>
<term>Saponines (administration et posologie)</term>
<term>Saponines (immunologie)</term>
<term>Vaccins (administration et posologie)</term>
<term>Vaccins (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Adjuvants, Pharmaceutic</term>
<term>Cholesterol</term>
<term>Phospholipids</term>
<term>Saponins</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cholesterol</term>
<term>Phospholipids</term>
<term>Saponins</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Adjuvants pharmaceutiques</term>
<term>Cholestérol</term>
<term>Phospholipides</term>
<term>Saponines</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cholestérol</term>
<term>Phospholipides</term>
<term>Saponines</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques comme sujet</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Combinations</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Association médicamenteuse</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The ISCOMATRIX adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17931156</PMID>
<DateCompleted><Year>2007</Year>
<Month>11</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<Issue>5</Issue>
<PubDate><Year>2007</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Expert review of vaccines</Title>
<ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation>
</Journal>
<ArticleTitle>ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.</ArticleTitle>
<Pagination><MedlinePgn>761-72</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The ISCOMATRIX adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drane</LastName>
<ForeName>Debbie</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria, Australia. debbie.drane@csl.com.au</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gittleson</LastName>
<ForeName>Charmaine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Boyle</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Maraskovsky</LastName>
<ForeName>Eugene</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Rev Vaccines</MedlineTA>
<NlmUniqueID>101155475</NlmUniqueID>
<ISSNLinking>1476-0584</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000277">Adjuvants, Pharmaceutic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493786">ISCOMATRIX</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber>
<NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000277" MajorTopicYN="N">Adjuvants, Pharmaceutic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012503" MajorTopicYN="N">Saponins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>30</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>12</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17931156</ArticleId>
<ArticleId IdType="doi">10.1586/14760584.6.5.761</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><noCountry><name sortKey="Boyle, Jeff" sort="Boyle, Jeff" uniqKey="Boyle J" first="Jeff" last="Boyle">Jeff Boyle</name>
<name sortKey="Gittleson, Charmaine" sort="Gittleson, Charmaine" uniqKey="Gittleson C" first="Charmaine" last="Gittleson">Charmaine Gittleson</name>
<name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Drane, Debbie" sort="Drane, Debbie" uniqKey="Drane D" first="Debbie" last="Drane">Debbie Drane</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B59 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:17931156
   |texte=   ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:17931156" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020

	Serveur d'exploration sur le peuplier
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le peuplier

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki